TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Conditions: Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7 ; Stage IIIC Breast Cancer AJCC v7 Interventions: Biological: Pertuzumab; Other: Placebo Administration; Biological: Sargramostim; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Biological: Vaccine Therapy Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Research